In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells

RT @TAGHIVscience: In vitro Evidence that Combination Therapy with CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Targ…

RT @TAGHIVscience: In vitro Evidence that Combination Therapy with CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Targ…

In vitro Evidence that Combination Therapy with CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent #HIV Reservoir in CD4+ CD2hi Memory T Cells https://t.co/z2M8rXjB1q

In vitro Evidence That #Combination #Therapy With #CD16-Bearing #NK-92 Cells and FDA-Approved #Alefacept Can Selectively Target the Latent #HIV Reservoir in #CD4+ #CD2hi Memory T Cells. #ADCC #CD16 #CD2 #NK92 #TCells @FoxChaseCancer https://t.co/87dSMW7SMB